• Product NameMGCD-265
• Brief DescriptionInhibitors
• Purification98.06%
• Biological ActivityMGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.
• Target Namec-Met/HGFR inhibitor; VEGFR inhibitor
• CAS No. 875337-44-3
• Calculated MW 517.6
• Formulation C26H20FN5O2S2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1C=NC(=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=CC=C4)C=C3F)=C2S1 |c:2,4,11,28,30,33,36,t:7,9,15,17,26|
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:Met; RON; VEGFR1; VEGFR2; VEGFR3
  Boling pt:
  Melting pt:
  Solubility:DMSO:104 mg/mL (200.92 mM)Ethanol:<1 mg/mL (<1 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Bonfils C. et al. AACR 2012 Annual Meeting, 2012. Abstract 1790.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting